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ABSTRACT 
 
Background: limited data are available on the clinical course of patients with history of atrial 
fibrillation (AF) when admitted in an intensive care environment. We aimed to describe the 
occurrence of major adverse events in AF patients admitted to a stepdown care unit (SDU) and 
to analyse clinical factors associated with outcomes, impact of dicumarolic oral anticoagulant 
(OAC) therapy impact and performance of clinical risk scores in this setting. 
Materials and Methods: Single-center, observational retrospective analysis on a population 
of subjects with AF history admitted to a SDU. Therapeutic failure (composite of transfer to 
ICU or death) was considered the main study outcome. Occurrence of stroke and major 
bleeding (MH) were considered as secondary outcomes. The performance of clinical risk 
scores was evaluated. 
Results: 1430 consecutive patients were enrolled. 194 (13.6%) reported the main outcome. 
Using multivariate logistic regression, age (odds ratio [OR]:1.03, 95% confidence interval 
[CI]:1.01-1.05), acute coronary syndrome (OR:3.10,95%CI:1.88-5.12), cardiogenic shock 
(OR:10.06,95%CI:5.37-18.84), septic shock (OR:5.19,95%CI:3.29-18.84), acute respiratory 
failure (OR:2.49,95%CI:1.67-3.64) and OAC use (OR:1.61,95%CI:1.02-2.55) were 
independently associated with main outcome. OAC prescription was associated with stroke 
risk reduction and to both MH and main outcome risk increase. CHA2DS2-VASc (c-
index:0.545, p=0.117 for stroke) and HAS-BLED (c-index:0.503, p=0.900 for MH) did not 
significantly predict events occurrence. 
Conclusions: In critically-ill AF patients admitted to a SDU, adverse outcomes are highly 
prevalent. OAC use is associated to an increased risk of therapeutic failure, clinical scores seem 
unhelpful in predicting stroke and MH, suggesting a highly individualized approach in AF 
management in this setting. 
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INTRODUCTION 
Atrial fibrillation (AF) is the most common sustained arrhythmia observed in general 
population[1] and several groups of hospitalized patients[2]. Among critically-ill subjects 
admitted in intensive care units (ICU), pre-existing and new-onset AF can be observed in 1 out 
of 3 patients[3]. New-onset AF has a prevalence between 5-46% and represents 52% of the 
atrial arrhythmias in ICU[2,3]. Pre-existing AF follows the prevalence of the general 
population, and is present in 9% in critically-ill patients admitted to ICU[3]. 
AF is associated to an increased risk of stroke, cardiovascular events and cardiovascular or all-
cause death[1,4]. In the context of critically-ill patients, AF is associated to a deterioration of 
haemodynamic state[3], as well as an increased stroke risk[5], acute decompensated heart 
failure (AHF)[6] and death[7]. In hospitalized patients new-onset AF does not independently 
predict in-hospital death[8], pre-existing AF is an independent risk factor for in-hospital 
mortality and worse functional outcomes[9,10]. In order to evaluate the baseline 
thromboembolic and bleeding risk and to prevent stroke and major bleeding occurrence, 
clinical prognostic scores are commonly used[11]. Nevertheless, their role for risk stratification 
in critically-ill patients is debated[12].  
Medical subjects at risk of clinical deterioration are admitted from emergency department to 
stepdown units (SDU) in order to optimize patient’s care[13].  Main objective of this study was 
to evaluate therapeutic failure, defined as the composite of death or ICU transfer in critically-
ill patients with pre-existing AF admitted to a SDU. Second, we evaluated thromboembolic 
and haemorragic events occurrence and their relationship with clinical prognostic scores. 
Finally, we evaluated the adherence to European Society of Cardiology (ESC) AF guidelines’ 
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recommendations[1] regarding oral anticoagulation with vitamin K antagonists (OAC) and its 
association with study outcomes. 
METHODS 
Study Cohort and Baseline Characteristics 
To evaluate study objectives, we retrospectively analysed a cohort of critically-ill patients with 
pre-existing AF admitted to the internal medicine department of the Azienda Ospedaliero-
Universitaria “Ospedali Riuniti”, Ancona, Italy. Since January 01st 2002 the department 
adopted an electronic medical record system (eMRS) for inpatients’ management that allowed 
us to interrogate the main database to select patients characterized by a specific diagnosis. All 
diagnoses in the eMRS are coded according to ICD-9-CM: we selected all consecutive patients 
admitted with a concurrent diagnosis of AF (ICD-9:427.31) from inception to August 03rd 
2007, in order to optimize data collection and to obtain a homogenous population in terms of 
clinical management and antithrombotic drugs use. We obtained from the eMRS and from the 
detailed examination of discharge reports all the data regarding demographics, history of risk 
factors and comorbidities, admission diagnoses, concurrent clinical events and antithrombotic 
drugs use. The study was approved by the institutional review board (Prot.168/2018,June 
21st,2018). 
The data that support the findings of this study are openly available in Mendeley Data at 
http://doi.org/10.17632/c87p293wpb.4[14]. 
Atrial Fibrillation 
The eMR contained patient’s history, his clinical course, electrocardiographic, 
echocardiographic and cardiac monitor data. We retrieved AF presence and type (paroxysmal, 
persistent or permanent) according to the definition current at the moment of the study. Patients 
developing AF during the hospitalization with a history of known paroxysmal AF were 
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considered, whereas subjects developing new-onset AF were excluded. We excluded all stable 
patients admitted for a programmed cardioversion procedure for AF rhythm control. 
Study Population 
Our SDU, according to the common definition[13], admits patients from the emergency 
department if affected by severe medical pathologies requiring an intermediate level of care, 
such as continuous electrocardiographic monitoring, inotropic or vasopressor support, non-
invasive ventilation and renal replacement therapy, but still not necessitating of invasive 
ventilation or ICU care.  
The acute pathologies considered for SDU admission were AHF, acute coronary syndromes 
(ACS), acute respiratory failure (ARF), acute kidney injury (AKI), infections, acute neurologic 
disorders, septic shock (SS), cardiogenic shock (CS), alone or in combination. Syncope and 
trauma were considered only as complicating conditions of the above-mentioned medical 
pathologies. 
Study Outcomes and Concurrent Clinical Events 
The main study outcome was the composite of death occurrence during SDU stay or ICU 
transfer due to the worsening of clinical conditions, requiring a more intensive and invasive 
management according to the clinical evaluation of the attending physicians. We also evaluated 
these events separately. The occurrence of concurrent clinical events during the SDU stay was 
also reported, with a specific interest in reporting thromboembolic (incident stroke or transient 
ischemic attack [TIA]) and major bleeding events. Concurrent clinical events were clinically 
defined by the attending physicians. 
Prognostic Clinical Scores 
In order to analyse the predictive ability of prognostic clinical risk scores, CHA2DS2-VASc 
and HAS-BLED scores were calculated according to the original schemes[11]. High 
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thromboembolic risk was defined as CHA2DS2-VASc ≥2, high bleeding risk as HAS-BLED 
≥3[11]. 
Guidelines Adherence 
Adherence to recommendations in terms of antithrombotic treatment was evaluated according 
to ESC guidelines[1]: patients’ treatment with antiplatelet drugs and OAC was defined as 
adherent to recommendations, undertreatment or overtreatment. 
Statistical Analysis 
Continuous variables were reported as mean and standard deviation or median and interquartile 
range, according to a normal or non-normal distribution of values. The statistical difference 
between subgroups was evaluated with t-test and ANOVA or with Mann-Whitney U-test and 
Kruskal-Wallis. Categorical variables were reported as number percentages, differences were 
evaluated with χ2 test. 
The association of the clinical factors with the main outcome was evaluated with logistic 
regression analysis. Demographic and clinical variable differences between patients with and 
without the main outcome were first assessed with univariate analysis; then all the variables 
associated with the main outcome with a p≤0.10 were included in multivariate analysis.  
The association between risk scores and adverse clinical events was performed with a logistic 
regression model adjusted for AF type and OAC use. Risk scores predictivity was expressed 
using c-index. Sensitivity, specificity, positive predictive value (PPV) and negative predictive 
value (NPV) were calculated according to high thromboembolic and high bleeding risks cut-
offs. 
The association between guidelines adherence and outcomes was analysed with a logistic 
regression model, adjusted for all clinical variables different between patients adherent and not 
adherent to guidelines and that were significantly associated at univariate analysis. We 
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considered as statistically significant a p-value≤0.05 for two-tailed tests. Statistical analyses 
were performed with SPSS 25.0 (IBM, USA). 
RESULTS 
1705 consecutive patients were retrieved through eMRS. After excluding those admitted for a 
planned cardioversion procedure, we included 1430 patients. From this cohort, we recorded 
194(13.6%) composite outcome events, including 160 deaths (11.2%) and 34 ICU transfers 
(2.4%). 
Baseline characteristics according to the occurrence of the composite outcome are summarised 
in Table 1. Patients reporting the composite outcome were significantly older, less burdened 
by hypertension and mitral valve disease (Table 1, Panel A and B), had less syncope and trauma 
but more ACS, CS, SS, ARF and infections than those without (Table 1, Panel C). Both 
admission systolic and diastolic blood pressures were significantly lower in those reporting the 
composite outcome (both p<0.001) and, in a subgroup where data about left ventricular 
function were available, reduced function was associated with composite outcome (p<0.001) 
(Table 1).  
Patients experiencing the composite outcome were more treated with anticoagulants, more 
likely OAC than low-molecular weight heparin (LMWH), and less treated with antiplatelet 
drugs than those that did not experience the outcome (Table 1, Panel D). Subjects sustaining 
the composite outcome were less likely treated with angiotensin converting enzyme 
inhibitors/angiotensin receptor blockers (p<0.001) and class IC antiarrhythmic drugs(p=0.008) 
but were more likely treated with inotropic drugs (p<0.001) (Table 1, Panel E). 
The final multivariate logistic regression model found that age (odds ratio [OR]:1.03,95% 
confidence interval[CI]:1.01-1.05), ACS (OR:3.10,95%CI:1.88-5.12), CS 
(OR:10.06,95%CI:5.37-18.84), SS (OR:5.19,95% CI: 3.29-18.84), ARF (OR:2.49,95% 
CI:1.67-3.64) and OAC (OR:1.61,95% CI:1.02-2.55) were associated with the occurrence of 
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composite outcome (Table 2). Conversely, hypertension, mitral valve disease, admission 
diastolic blood pressure and antiplatelet drugs use were inversely associated with the composite 
outcome (Table 2). 
Guidelines Recommendation Adherence and Relationship with Outcomes 
According to ESC 2016 guidelines, 642(44.9%) patients were guideline-adherent, 540 (37.8%) 
were undertreated and 24 (17.3%) were overtreated. Stroke/TIA was lowest in guideline-
adherent patients (p<0.001)[Figure 1], but prevalence of both major bleeding and composite 
outcome was higher (p<0.001 and p=0.020, respectively)[Figure 1]. The final multivariable 
model (Table 3,Panel A) showed that undertreatment was associated with an increased 
stroke/TIA risk, with an inverse association with both major bleeding and composite outcome. 
Overtreatment only showed a nonsignificant trend for stroke/TIA (Table 3,Panel A). 
Thromboembolic and Bleeding Risks and Relationship with Outcomes 
At baseline, there was no difference in terms of thromboembolic risk according to CHA2DS2-
VASc score between patients that experienced the composite outcome and those that did not 
experience it. HAS-BLED score, as well the proportion of patients with high bleeding risk were 
lower (both p<0.001) in patients that reported the composite outcome (Table 1,Panel F). No 
significant difference was found in the distribution of the composite outcome according to 
CHA2DS2-VASc score (p=0.501). Conversely, the composite outcome occurred more 
frequently in patients with a lower HAS-BLED score (p<0.001). 
Examination of stroke/TIA prevalence according to CHA2DS2-VASc score and major bleeding 
prevalence according to HAS-BLED score found no significant differences (Table 3, Panel B). 
The predictive ability of the two scores regarding the respective events was non-significant 
(CHA2DS2-VASc:0.545;95%CI:0.489-0.601; HAS-BLED:0.503;95%CI:0.453-0.554). 
Considering high thromboembolic risk, we found high sensitivity (93.4%,95%CI:90.9-99.0%), 
high NPV (95.0%,95%CI:87.6-98.1%) and low specificity and PPV (Table 3, Panel B) of 
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CHA2DS2-VASc ≥2 for stroke/TIA. Regarding bleeding risk, intermediate values for both 
sensitivity (46.6%,95%CI:37.9-55.5%) and specificity (57.1%,95%CI:54.4-59.8%) were 
found, while high NPV (91.3%,95%CI:89.8-92.5%) and very low PPV were reported (Table 
3, Panel B). 
DISCUSSION 
In this study we found that in a cohort of critically-ill patients with a diagnosis of AF admitted 
to a SDU the composite outcome of death and ICU transfer was fairly prevalent, usually 
amongst older patients characterized by a worse and more severe clinical status. OAC use was 
associated to an increased risk of the composite outcome, while no impact of LMWH and an 
inverse association with antiplatelet drugs use was found. Guidelines adherence was associated 
with a stroke/TIA risk reduction, while undertreatment was inversely associated with the 
occurrence of major bleeding and the composite outcome. CHA2DS2-VASc and HAS-BLED 
scores were not associated with the stroke/TIA and major bleeding occurrence, nor showed 
significant predictive ability for these events; both scores demonstrated the ability of 
identifying patients with a very low risk.  
The issue of new-onset AF in patients admitted to intensive care environment has been largely 
investigated and reported[15]. Several clinical risk factors, both related to the previous medical 
history and the severity of the acute condition, were positively associated to AF 
occurrence[15]. New-onset AF has been found associated with short- and long-term adverse 
outcomes[3]. 
Conversely, only scarce evidence exists in relation to the relative impact of pre-existing AF on 
the risk of adverse outcomes in ICU[8]. Indeed, our study provides the first European 
perspective about the high risk of major adverse events in critically-ill patients with pre-
existing AF. The evidence of 13.6% of patients reporting death or being transferred to the ICU 
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requires careful consideration given the implications in terms of its impact on patients and 
healthcare resource use.  
Our results are strengthened by a previous study, which reported a similar rate of major adverse 
events among a US cohort of patients admitted to medical ICU, similar to that of the SDU[8]. 
AF patients have an increased risk of death[16], but we underlined how in this context the risk 
of death is not associated to any of the classical AF-related risk factors rather than to the acute 
illness and depends on the overall clinical complexity of patients managed in this highly 
specific setting, as acute coronary syndrome, cardiogenic shock, acute respiratory failure, all 
conditions associated with a known increased thromboembolic and bleeding risks. 
One of the most complex issues in the intensive care setting related to the management of OAC 
therapy. In a study performed in the Quebec region, considering patients with acute illnesses 
such as ACS, ARF or sepsis that developed AF, OAC use was not associated with a clinical 
benefit in terms of stroke risk reduction, but increased significantly the bleeding risk, especially 
in patients with a high bleeding risk (HAS-BLED ≥3)[17]. Several viewpoints emphasize the 
difficulty of taking the decision whether or not to prescribe OAC in ICU patients who 
developed AF, and it may be more relevant to consider OAC after ICU discharge, particularly 
for those with high thromboembolic risk[3]. Of note, ICU patients with new-onset AF also 
have an increased long-term risk for stroke and death[18].  Results of the multivariate 
regression analysis presented raise serious concerns about keeping anticoagulation in AF 
patients when admitted to intensive care. Conversely, LMWH use seems not to carry further 
risk, while antiplatelet drugs use seems associated to a lower risk of composite outcome. Even 
though we showed only an association, since the study design did not allow to provide any 
causal inference, we can postulate that the known anti-inflammatory effect of antiplatelet 
drugs[19] could be implied in the inverse relationship with the composite outcome we 
described. 
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Several studies have addressed the relationship between guidelines adherence and improved 
outcomes in AF patients[20]. If, expectedly, those patients prescribed as undertreated showed 
an association with an increased stroke risk and lower major bleeding risk, the inverse 
association described with the composite outcome underlines how maintaining OAC in AF 
during SDU staying could not be indicated. In the context of intensive care, we are not able to 
provide specific “general” recommendations on how to manage thromboembolic risk in AF 
patients, rather a careful consideration of clinical status and an individual risk assessment. 
Specific studies in this context are clearly demanded to elucidate what would be the best 
approach. 
CHA2DS2-VASc and HAS-BLED scores are validated and used to evaluate thromboembolic 
and bleeding risk in AF patients[21], being associated and able to predict the occurrence of 
death in AF patients[22].  Nevertheless, validation of these scores is lacking in ICU. Despite 
the high rate of reported events, our data show that CHA2DS2-VASc and HAS-BLED are 
unable to predict stroke and major bleeding. The high NPV documented for both the scores 
confirms their ability to identify ‘low risk’ patients.  In a recent systematic review of the 
evidence available about use of scores in stroke and major bleeding prediction, all available 
risk scores report an overall moderate predictive ability, with the CHA2DS2-VASc and HAS-
BLED the best option in the daily clinical practice[21]. Clinical scores have c-indexes 
approximately around 0.67, hence their use cannot be absolutized and replace the physicians’ 
clinical judgement and appropriate clinical assessment[21]. In this context, both scores were 
unable to predict adverse events in intensive care AF patients, and this underlines how clinical 
complexity overcomes the usual pathophysiological processes that lead to stroke and major 
bleeding, making it more unpredictable.  
In order to correctly interpret our findings is important to make one important consideration. 
Both CHA2DS2-VASc and HAS-BLED scores were originally developed from general AF 
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patients’ cohorts and tested on 1-year outcomes[23,24]. Notwithstanding, since then both the 
scores were largely validated in various cohorts and tested on variable follow-up times[25–27]; 
indeed the use of both the scores are currently recommended from most of the international 
clinical AF guidelines[28]. 
Limitations 
The main limitation is related to the study design, being a retrospective observational analysis 
of a cohort not primarily identified for research purposes. Second, in the cohort of patients 
analysed only vitamin K antagonists were used as OAC. Third, we evaluated adherence to the 
application of current indications for anticoagulant therapy in a retrospective cohort, when the 
current reference guidelines had not been published, even though this was done exclusively 
exploratorily, allowed us to project the current guidelines recommendations to our cohort. 
While these limitations need to be accounted extending our findings to the overall AF 
population, the evidence we provided brings relevant implications in terms of clinical 
management of AF patients admitted to SDU and ICU.   
CONCLUSIONS 
In critically-ill AF patients admitted to a SDU, adverse outcomes are highly prevalent. OAC 
use is associated to an increased risk for the composite outcome, even in those patients correctly 
prescribed according to guidelines recommendations. Clinical scores may be unhelpful in 
predicting stroke and major bleeding occurrence, suggesting a highly individualized approach 
in evaluating the risk of adverse events and in the decision-making process of prescribing OAC 
therapy. 
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FIGURE LEGENDS 
 
Figure 1: Rate of Major Adverse Outcomes according to Adherence to Guidelines 
 
Legend: GLs= Guidelines, TIA= Transient ischemic attack. 
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Table 1: Baseline Characteristics at Admission in Sub-Intensive Unit (cont.) 
 Composite Outcome p 
 No 
N= 1236 
Yes 
N= 194 
A) Demographics    
Age, years median [IQR] 81 [75-85] 83 [77-89] <0.001 
Female Sex, n (%) 753 (49.9) 90 (46.2) 0.329 
Type of AF, n (%) 
Paroxysmal 
Persistent 
Permanent 
 
220 (18.6) 
292 (24.7) 
668 (56.6) 
 
24 (12.8) 
57 (30.3) 
107 (56.9) 
0.077 
SBP, mmHg median [IQR] 130 [110-140] 90 [80-122] <0.001 
DBP, mmHg median [IQR] 80 [70-80] 60 [40-80] <0.001 
LV Function, n (%) 524 
Preserved 
Reduced 
 
326 (67.4) 
158 (32.6) 
 
17 (42.5) 
23 (57.5) 
0.001 
B) Previous Clinical History    
Hypertension, n (%) 637 (51.5) 64 (33.0) <0.001 
Diabetes Mellitus, n (%) 226 (18.3) 34 (17.5) 0.799 
Anaemia, n (%) 114 (9.2) 17 (8.8) 0.836 
Coronary Artery Disease, n (%) 531 (43.0) 78 (40.2) 0.471 
Peripheral Artery Disease, n (%) 131 (10.6) 16 (8.2) 0.316 
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Table 1: Baseline Characteristics at Admission in Sub-Intensive Unit (cont.) 
Chronic Heart Failure, n (%) 581 (47.0) 88 (45.4) 0.669 
pCVP, n (%) 183 (14.8) 27 (13.9) 0.745 
eCVP, n (%) 29 (2.3) 1 (0.5) 0.098 
Stroke/TIA, n (%) 258 (20.9) 34 (17.5) 0.282 
Mitral Disease, n (%) 195 (15.8) 15 (7.7) 0.003 
Aortic Disease, n (%) 151 (12.2) 16 (8.2) 0.109 
COPD, n (%) 340 (27.5) 54 (27.8) 0.925 
Hepatic Disease, n (%) 35 (2.8) 7 (3.6) 0.551 
CKD, n (%) 230 (18.6) 39 (20.1) 0.620 
Previous Major Bleeding, n (%) 66 (5.3) 5 (2.6) 0.100 
Neoplasm, n (%) 210 (17.0) 44 (22.7) 0.054 
Comorbidities, n median [IQR] 3 [2-4] 2 [2-3] 0.114 
C) Concurrent Clinical Events    
Stroke/TIA, n (%) 90 (7.3) 20 (10.3) 0.141 
Major Bleeding, n (%) 110 (8.9) 23 (11.9) 0.188 
Syncope, n (%) 68 (5.5) 2 (1.0) 0.007 
Acute Neurologic Disorders, n (%) 47 (3.8) 6 (3.1) 0.627 
Trauma, n (%) 78 (6.3) 5 (2.6) 0.039 
ACS, n (%) 160 (12.9) 50 (25.8) <0.001 
Acute Heart Failure, n (%) 669 (54.1) 99 (51.0) 0.421 
Cardiogenic Shock, n (%) 28 (2.3) 43 (22.2) <0.001 
Septic Shock, n (%) 106 (8.6) 74 (38.1) <0.001 
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Table 1: Baseline Characteristics at Admission in Sub-Intensive Unit (cont.) 
AKI, n (%) 58 (4.7) 10 (5.2) 0.779 
Acute Respiratory Failure, n (%) 319 (25.8) 77 (39.7) <0.001 
Infections, n (%) 330 (26.7) 102 (52.6) <0.001 
D) Antithrombotic Therapies    
Anticoagulant Drugs, n (%) 
None 
Any Anticoagulant 
 
454 (36.7) 
782 (63.3) 
 
46 (23.7) 
148 (76.3) 
<0.001 
 
Type of Anticoagulant, n (%) 
LMWH 
OAC 
 
312 (39.9) 
470 (60.1) 
 
65 (43.9) 
83 (56.1) 
0.361 
Antiplatelet Drugs, n (%) 515 (41.7) 55 (28.4) <0.001 
E) Other Treatments    
ACEi/ARBs, n (%) 633 (51.9) 16 (8.5) <0.001 
Diuretics, n (%) 925 (75.8) 144 (76.2) 0.912 
Inotropic Drugs, n (%) 273 (22.4) 157 (82.6) <0.001 
Amiodarone, n (%) 381 (31.2) 54 (28.7) 0.493 
Propafenone/Flecainide, n (%) 56 (4.6) 1 (0.5) 0.008 
Sotalol, n (%) 16 (1.3) 0 (0.0) 0.113 
F) Thromboembolic and Bleeding Risk 
CHA2DS2-VASc, median [IQR] 4 [3-5] 4 [3-5] 0.057 
CHA2DS2-VASc, mean (SD) 4.28 (1.68) 4.04 (1.72) 0.774 
CHA2DS2-VASc ≥2, n (%) 1170 (94.7) 180 (92.8) 0.290 
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Table 1: Baseline Characteristics at Admission in Sub-Intensive Unit (cont.) 
HAS-BLED, median [IQR] 2 [2-3] 2 [1-3] <0.001 
HAS-BLED, mean (SD) 2.38 (1.08) 2.07 (0.95) <0.001 
HAS-BLED ≥3, n (%) 563 (45.6) 55 (28.4) <0.001 
Legend: AF= Atrial Fibrillation; ACS= Acute Coronary Syndrome; AKI= Acute Kidney 
Injury; CKD= Chronic Kidney Disease; COPD= Chronic Obstructive Pulmonary Disease; 
eCVP= Electrical Cardioversion Procedure; pCVP= Pharmacological Cardioversion 
Procedure; IQR= Interquartile Range; LMWH= Low-Molecular Weight Heparin; OAC= Oral 
Anticoagulant; TIA= Transient Ischemic Attack. 
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Table 2: Multivariate Logistic Regression Analysis for Composite Outcome Occurrence 
 OR 95% CI p 
Age (per year) 1.03 1.01-1.05 0.011 
DBP (per mmHg) 0.98 0.95-0.99 0.023 
Hypertension 0.54 0.37-0.79 0.001 
Mitral Disease 0.47 0.24-0.92 0.028 
ACS 3.10 1.88-5.12 <0.001 
Cardiogenic Shock 10.06 5.37-18.84 <0.001 
Septic Shock 5.19 3.29-8.19 <0.001 
Acute Respiratory Failure 2.46 1.67-3.64 <0.001 
Anticoagulant Drugs 
None (reference) 
LMWH 
OAC 
 
- 
1.05 
1.61 
 
- 
0.64-1.71 
1.02-2.55 
 
- 
0.857 
0.040 
Antiplatelet Drugs 0.61 0.40-0.93 0.021 
Legend: ACS= Acute Coronary Syndrome; CI= Confidence Interval; LMWH= Low-
Molecular Weight Heparin; OAC= Oral Anticoagulant; OR= Odds Ratio; TEE= 
Thromboembolic Events; TIA= Transient Ischemic Attack. 
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Table 3: Guidelines Adherence, Clinical Risk Scores and Major Adverse Events 
A) Multivariable-Adjusted Association between Guidelines Adherence and Major Adverse 
Events 
 Stroke/TIA Major Bleeding Composite Outcome 
 OR  
(95% CI) 
p OR  
(95% CI) 
p OR  
(95% CI) 
p 
GLs Adherent 
(ref.) 
- - - - - - 
Undertreated 2.38  
(1.45.-
3.91) 
0.001 0.30  
(0.18-0.48) 
<0.001 0.63  
(0.42-0.97) 
0.034 
Overtreated 1.75 
(0.90-3.39) 
0.097 0.67  
(0.39-1.15) 
0.143 0.83  
(0.48-1.41) 
0.481 
B) Association between Risk Scores and Concurrent Clinical Events and Predictive 
Analysis 
 OR  
(95 %CI)* 
p c-index 
(95%CI) 
p 
CHA2DS2-VASc  
for Stroke/TIA 
1.09  
(0.96-1.22) 
0.175 0.545  
(0.489-0.601) 
0.117 
HAS-BLED  
for Major Bleeding 
1.07  
(0.90-1.27) 
0.477 0.503  
(0.453-0.554) 
0.900 
 Sensitivity 
(95% CI) 
Specificity 
(95% CI) 
PPV  
(95% CI) 
NPV  
(95% CI) 
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CHA2DS2-VASc 
≥2 for Stroke/TIA 
93.4%  
(90.9-99.0%) 
5.8%  
(4.6-7.1%) 
7.8%  
(6.4-9.2%) 
95.0%  
(87.6-
98.1%) 
HAS-BLED ≥3  
for Major Bleeding 
46.6%  
(37.9-55.5%) 
57.1%  
(54.4-59.8%) 
10.0%  
(8.4-11.9%) 
91.3%  
(89.8-
92.5%) 
Legend: *adjusted for type of AF and anticoagulant treatment; CI= Confidence interval; 
GLs= Guidelines; NPV= Negative predictive value; OR= Odds ratio; Positive predictive 
value; TEE= Thromboembolic Events; TIA= Transient ischemic attack. 
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eFigure 1: Adherence to European Society of Cardiology Guidelines Recommendations 
 
Legend: ACS= acute coronary syndrome. 
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eFigure 2: Thromboembolic and Bleeding Risk according to Composite Outcome 
Occurrence  
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eTable 1: Multivariable-Adjusted Association between Guidelines Adherence and Major Adverse Events 
 Stroke/TIA Major Bleeding Composite Outcome 
 OR (95% CI) p OR (95% CI) p OR (95% CI) p 
GLs Adherent (ref.) - - - - - - 
Undertreated 2.38 (1.45.-3.91) 0.001 0.30 (0.18-0.48) <0.001 0.63 (0.42-0.97) 0.034 
Overtreated 1.75 (0.90-3.39) 0.097 0.67 (0.39-1.15) 0.143 0.83 (0.48-1.41) 0.481 
Legend: CI= Confidence interval; GLs= Guidelines; TIA= Transient ischemic attack.  
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eTable 2: Major Adverse Events Rate according to Risk Scores 1 
CHA2DS2-VASc 
Stroke/TIA 
n (%) 
HAS-BLED 
Major Bleeding 
n (%) 
0 0 (0.0) 0 3 (7.3) 
1 4 (6.1) 1 27 (9.9) 
2 10 (7.4) 2 41 (8.2) 
3 15 (6.1) 3 49 (11.5) 
4 27 (8.1) 4 10 (6.2) 
5 24 (7.7) 5 3 (11.1) 
6 14 (7.5) 6 0 (0.0) 
7 13 (12.6)   
8 3 (11.5)   
9 0 (0.0)   
Legend: TIA= Transient ischemic attack. 2 
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